Illumina announced a definitive agreement to acquire SomaLogic for up to $425 million, strategically enhancing its proteomics capabilities and bolstering its multiomics portfolio. This transaction builds on a multi-year collaboration between the two companies to integrate SomaLogic's DNA aptamer-based proteomics technology with Illumina's next-generation sequencing platforms. The acquisition includes proprietary assays, a CLIA-certified lab in Boulder, Colorado, and approximately 250 employees. Illumina aims to accelerate biomarker discovery and disease profiling through this expanded multiomics approach, advancing next-generation diagnostic and therapeutic development.